Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 6/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20931310 | 0.87 | PLAT (0.38) | PLATALDH1A1CYP2C19ALOX15BCA1 | |
| SCHEMBL20914105 | 0.85 | PLAT (0.42) | PLATALDH1A1CYP2C19ALOX15BKDM4E | |
| SCHEMBL20914007 | 0.84 | PLAT (0.43) | PLATALDH1A1CYP2C19ALOX15BKDM4E | |
| SCHEMBL20914241 | 0.80 | MEN1 (0.42) | ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL20914303 | 0.80 | PLAT (0.46) | PLATALDH1A1KDM4ENPC1GAA | |
| SCHEMBL20914226 | 0.77 | PLAT (0.47) | PLAT | |
| SCHEMBL20914147 | 0.77 | PLAT (0.38) | PLATALDH1A1KDM4ENPC1GAA | |
| SCHEMBL20931257 | 0.77 | MDM2 (0.38) | KDM4E | |
| SCHEMBL20837037 | 0.77 | P2RY6 (0.37) | ALDH1A1KDM4ENPC1MAPTRAB9A | |
| SCHEMBL20914302 | 0.76 | CDK5 (0.35) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| CN-111212839-A | Pyrazolopyrimidinone compounds and uses thereof | 艾杜罗生物科技公司 | 2020-05-29 | — | — | CN | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | PLAT 1323/4885ALDH1A1 1246/4885CYP2C19 379/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | PLAT 1323/4885ALDH1A1 1246/4885CYP2C19 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.